Eylea Market by Indication (Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion), Dosage Frequency (As Needed, Bimonthly, Monthly), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Eylea Market was valued at USD 7.25 billion in 2024 and is projected to grow to USD 7.71 billion in 2025, with a CAGR of 7.30%, reaching USD 12.75 billion by 2032.
A concise orientation to the Eylea therapeutic landscape explaining clinical foundations, stakeholder imperatives, and the strategic context for decision-making
Eylea remains a central therapeutic option in retinal disease management, offering a well-established mechanism of action that has shaped standards of care across multiple indications. Over the past decade, clinicians and payers have integrated Eylea into treatment algorithms for neovascular retinal disorders and diabetic eye disease, with clinical evidence reinforcing its efficacy and safety profile. As the clinical environment matures, stakeholders now face a more complex operating context in which novel therapies, shifting reimbursement frameworks, and supply chain dynamics converge to influence access and utilization.
Against this backdrop, strategic clarity is essential. Manufacturers must refine life-cycle plans that balance clinical differentiation with cost pressures, while providers need pragmatic protocols that preserve outcomes amid administrative and logistical constraints. Payers and procurement bodies are increasingly focused on total cost of care and long-term visual outcomes, which amplifies the value of robust real-world evidence and health economic modeling. This introduction sets the stage for a deeper evaluation of structural shifts, policy developments, segmentation-level implications, and actionable recommendations designed to equip clinical, commercial, and policy leaders with a clear line of sight into near-term and medium-term challenges and opportunities.
An analysis of converging clinical innovations, delivery technology advances, and health system reforms that are fundamentally altering retinal disease treatment dynamics
Several transformative shifts are reshaping the ophthalmology landscape and altering the competitive environment around Eylea. First, the acceleration of long-acting formulations and alternative delivery systems is changing treatment cadence and patient interaction patterns, prompting clinicians to reassess follow-up schedules and adherence expectations. Simultaneously, the emergence of next-generation biologics and intraocular implants has raised the bar for demonstrating incremental clinical benefit, intensifying the need for head-to-head and real-world comparative evidence.
Beyond product innovation, health systems are moving toward integrated care pathways that emphasize outcomes over procedure counts, which in turn affects contracting and reimbursement negotiations. Digital health capabilities, including remote monitoring and teleophthalmology, are reducing friction in chronic disease management but also shifting where and how value is captured. Supply chain modernization, heightened regulatory scrutiny, and geopolitical pressures are introducing new constraints on sourcing and distribution. Taken together, these forces are encouraging manufacturers to pursue differentiated evidence generation, more flexible commercial models, and deeper collaboration with providers and payers to sustain access and optimize patient outcomes.
A comprehensive examination of how the 2025 United States tariff changes disrupted sourcing, pricing, contracting, and supply resilience across the ophthalmic therapeutic supply chain
The introduction of United States tariff measures in 2025 created immediate and cascading effects across the ophthalmic pharmaceutical supply chain, influencing manufacturing economics, procurement practices, and clinical operations. Manufacturers faced higher input costs for certain raw materials and finished goods movement, prompting accelerated review of sourcing strategies and increased emphasis on nearshoring and qualified secondary suppliers. Distributors and specialty pharmacies adjusted inventory policies and logistics contracts to mitigate volatility, while health systems reassessed stocking practices and purchasing cadence to avoid exposure to rate oscillations.
Clinicians and provider organizations experienced the downstream implications as contracting teams negotiated more complex terms with suppliers and group purchasing organizations. Where cost pressures could not be absorbed, there was upward pressure on acquisition costs that required clinicians to provide more robust justification for treatment choices focused on long-term visual stability and downstream resource avoidance. Payers responded by intensifying prior authorization scrutiny, demanding more precise clinical documentation and outcomes data to support reimbursement for higher-cost therapies.
Importantly, the tariffs catalyzed strategic shifts rather than static distortions. Stakeholders invested in supply chain transparency, expanded use of predictive inventory analytics, and increased collaboration between manufacturers and providers to create contingency protocols that reduced the risk of treatment disruption. Contract language evolved to include more explicit force majeure and price-adjustment clauses, and risk-sharing constructs gained traction as a mechanism to balance access and affordability while protecting clinical standards. Policymakers and industry leaders now emphasize resilience and adaptability as central design criteria for future commercial agreements and distribution frameworks.
Insightful segmentation analytics connecting indication diversity, provider ecosystems, distribution pathways, and dosing frequencies to optimize clinical and commercial tactics
Segmentation-driven strategies are essential to align clinical value propositions with the distinct characteristics of patient populations, care settings, distribution pathways, and dosing regimens. When considering indication-level differentiation, attention must be directed to each therapeutic area such as Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, because clinical presentation, progression risk, and treatment responsiveness vary and therefore warrant tailored evidence packages and stewardship protocols. End-user segmentation further refines commercial and operational priorities: ambulatory surgical centers operate under different throughput, billing, and inventory constraints compared with hospitals and ophthalmic clinics, which informs distribution agreements, cold-chain logistics, and onsite administration resources.
Distribution-channel dynamics are equally influential. Hospital pharmacy procurement environments favor bundled contracting and integrated inventory management, while online pharmacy channels introduce patient-centric convenience and different compliance considerations, and retail pharmacies require tailored dispensing workflows and patient education tools. Dosing frequency segmentation-ranging from As Needed regimens to Bimonthly and Monthly schedules-impacts adherence, clinic capacity planning, and long-term cost and outcome narratives. Aligning clinical trial designs, real-world evidence initiatives, and commercial messaging to these intersecting segmentation dimensions enables more precise targeting of reimbursement dossiers, provider engagement, and patient support programs, thereby improving uptake and preserving continuity of care across diverse settings.
A regionally nuanced perspective on regulatory, reimbursement, and delivery variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated access strategies
Regional dynamics materially influence regulatory pathways, reimbursement frameworks, service delivery models, and commercial approaches. In the Americas, payer heterogeneity and a strong private provider network create an environment where differentiated clinical evidence and contracting flexibility determine formulary positioning and access pathways. The Americas also tend to emphasize outcomes-based agreements in targeted segments and prioritize rapid adoption in high-volume treatment centers, while supply chain logistics are impacted by domestic manufacturing capacity and cross-border trade policies.
The Europe, Middle East & Africa region presents a complex mosaic of national health systems, regulatory regimes, and procurement practices. Centralized reimbursement evaluations coexist with decentralized hospital procurement, which requires manufacturers to pursue both health technology assessment engagement and local stakeholder partnerships. Price sensitivity and tender-driven purchasing models in several markets necessitate robust health economic dossiers and strategic local partnerships to secure durable access.
In the Asia-Pacific region, diverse levels of clinical infrastructure and variable reimbursement pathways create both rapid-adoption opportunities and access challenges. Some markets are characterized by fast uptake of innovation when supported by strong clinician advocacy and favorable reimbursement, whereas others require tiered pricing models and focused capacity-building initiatives. Across all regions, cold-chain integrity, point-of-care training, and locally relevant evidence are core enablers of sustained adoption and equitable patient access.
Actionable company-level intelligence describing how manufacturers, service providers, and distribution partners are reshaping R&D, contracting, and supply strategies to protect access
Leading companies and strategic partners in the retinal therapeutics domain are adapting commercial models and R&D priorities to the changing environment. Manufacturers with established products are investing in life-cycle management through new formulations, label expansions, and evidence generation that supports differentiated clinical value. Strategic alliances with contract manufacturing organizations and specialty distributors are being strengthened to secure supply continuity and to manage tariff-related cost pressures. Innovative entrants and established competitors alike are prioritizing head-to-head comparative trials and real-world outcome studies to substantiate claims of extended durability or superior functional improvement.
Service providers, including ambulatory surgical centers and specialty clinics, are optimizing procedural workflows and revenue models to accommodate evolving dosing schedules and to maximize throughput without compromising patient care. Contracting intermediaries and payers are experimenting with outcomes-based arrangements and bundled payment models to align incentives across the care continuum. Across this ecosystem, organizations that invest in integrated evidence strategies, digital patient support tools, and robust cold-chain logistics are better positioned to manage complexity and to preserve access in constrained procurement environments.
Practical strategic and operational recommendations for manufacturers, providers, and payers to safeguard access and optimize outcomes amid evolving clinical and commercial pressures
Industry leaders should adopt a multifaceted playbook that balances clinical differentiation, cost containment, and supply resiliency. First, evidence strategies must be prioritized to demonstrate not only clinical efficacy but also functional outcomes and total cost of care benefits; investing in pragmatic trials and high-quality registries will strengthen reimbursement discussions and provider confidence. Second, supply chain diversification and qualification of alternative suppliers, including validated nearshore partners, will mitigate tariff and logistics risks while preserving service levels.
Commercial teams should design flexible contracting constructs that incorporate risk-sharing elements and outcome-based milestones, aligning incentives among manufacturers, payers, and providers. Operationally, investing in predictive inventory analytics and enhanced cold-chain monitoring will reduce stockouts and wastage while enabling smoother patient pathways. Additionally, tailored engagement models for different provider types-ambulatory surgical centers, hospitals, and ophthalmic clinics-will improve adoption and adherence to recommended protocols. Finally, prioritizing patient support programs and telehealth-enabled follow-up can maintain adherence across varied dosing frequencies and reduce no-show rates, thereby preserving visual outcomes and smoothing resource utilization.
A transparent description of the mixed-methods research approach combining primary stakeholder interviews, document review, and scenario analysis to underpin strategic conclusions
This analysis integrates qualitative and quantitative research methods to deliver balanced, actionable insights. Primary research included structured interviews with key opinion leaders, procurement specialists, supply chain executives, and clinical operations managers to capture frontline perspectives on treatment patterns, access challenges, and operational constraints. Secondary research drew on peer-reviewed literature, regulatory public records, clinical trial registries, and payer policy documents to validate clinical and policy trends. Supply chain mapping and tariff impact analysis used transaction-level logic and scenario planning to explore potential pathways for cost and availability fluctuations.
Findings were triangulated through cross-validation with real-world use cases and advisory input from practicing retinal specialists. Limitations include the inherent unpredictability of policy changes and the emergence of new therapeutic entrants whose long-term impact may extend beyond the temporal window of this research. Nevertheless, the methodological mix of primary stakeholder engagement, rigorous document review, and scenario analysis provides a robust foundation for strategic decision-making and for prioritizing follow-up analyses tailored to specific organizational needs.
A concise synthesis of strategic implications and the imperative for coordinated clinical, commercial, and operational responses to protect patient outcomes
In sum, the Eylea landscape is at an inflection point where clinical innovation, commercial pressure, and geopolitical considerations intersect to redefine access and delivery. Clinicians and providers must adapt care pathways to accommodate evolving dosing paradigms and to ensure continuity of care in the face of procurement volatility. Manufacturers and distribution partners need to double down on evidence generation, supply chain diversification, and flexible contracting to preserve access while demonstrating value.
The implications are clear: tactical adjustments alone will not suffice; coordinated strategies that align clinical, commercial, and operational stakeholders are required to protect patient outcomes and to sustain service delivery. Prioritizing resilient logistics, targeted evidence accumulation, and collaborative contracting will enable stakeholders to navigate near-term disruptions and to capture long-term opportunities as the retinal therapeutics ecosystem continues to evolve.
Note: PDF & Excel + Online Access - 1 Year
A concise orientation to the Eylea therapeutic landscape explaining clinical foundations, stakeholder imperatives, and the strategic context for decision-making
Eylea remains a central therapeutic option in retinal disease management, offering a well-established mechanism of action that has shaped standards of care across multiple indications. Over the past decade, clinicians and payers have integrated Eylea into treatment algorithms for neovascular retinal disorders and diabetic eye disease, with clinical evidence reinforcing its efficacy and safety profile. As the clinical environment matures, stakeholders now face a more complex operating context in which novel therapies, shifting reimbursement frameworks, and supply chain dynamics converge to influence access and utilization.
Against this backdrop, strategic clarity is essential. Manufacturers must refine life-cycle plans that balance clinical differentiation with cost pressures, while providers need pragmatic protocols that preserve outcomes amid administrative and logistical constraints. Payers and procurement bodies are increasingly focused on total cost of care and long-term visual outcomes, which amplifies the value of robust real-world evidence and health economic modeling. This introduction sets the stage for a deeper evaluation of structural shifts, policy developments, segmentation-level implications, and actionable recommendations designed to equip clinical, commercial, and policy leaders with a clear line of sight into near-term and medium-term challenges and opportunities.
An analysis of converging clinical innovations, delivery technology advances, and health system reforms that are fundamentally altering retinal disease treatment dynamics
Several transformative shifts are reshaping the ophthalmology landscape and altering the competitive environment around Eylea. First, the acceleration of long-acting formulations and alternative delivery systems is changing treatment cadence and patient interaction patterns, prompting clinicians to reassess follow-up schedules and adherence expectations. Simultaneously, the emergence of next-generation biologics and intraocular implants has raised the bar for demonstrating incremental clinical benefit, intensifying the need for head-to-head and real-world comparative evidence.
Beyond product innovation, health systems are moving toward integrated care pathways that emphasize outcomes over procedure counts, which in turn affects contracting and reimbursement negotiations. Digital health capabilities, including remote monitoring and teleophthalmology, are reducing friction in chronic disease management but also shifting where and how value is captured. Supply chain modernization, heightened regulatory scrutiny, and geopolitical pressures are introducing new constraints on sourcing and distribution. Taken together, these forces are encouraging manufacturers to pursue differentiated evidence generation, more flexible commercial models, and deeper collaboration with providers and payers to sustain access and optimize patient outcomes.
A comprehensive examination of how the 2025 United States tariff changes disrupted sourcing, pricing, contracting, and supply resilience across the ophthalmic therapeutic supply chain
The introduction of United States tariff measures in 2025 created immediate and cascading effects across the ophthalmic pharmaceutical supply chain, influencing manufacturing economics, procurement practices, and clinical operations. Manufacturers faced higher input costs for certain raw materials and finished goods movement, prompting accelerated review of sourcing strategies and increased emphasis on nearshoring and qualified secondary suppliers. Distributors and specialty pharmacies adjusted inventory policies and logistics contracts to mitigate volatility, while health systems reassessed stocking practices and purchasing cadence to avoid exposure to rate oscillations.
Clinicians and provider organizations experienced the downstream implications as contracting teams negotiated more complex terms with suppliers and group purchasing organizations. Where cost pressures could not be absorbed, there was upward pressure on acquisition costs that required clinicians to provide more robust justification for treatment choices focused on long-term visual stability and downstream resource avoidance. Payers responded by intensifying prior authorization scrutiny, demanding more precise clinical documentation and outcomes data to support reimbursement for higher-cost therapies.
Importantly, the tariffs catalyzed strategic shifts rather than static distortions. Stakeholders invested in supply chain transparency, expanded use of predictive inventory analytics, and increased collaboration between manufacturers and providers to create contingency protocols that reduced the risk of treatment disruption. Contract language evolved to include more explicit force majeure and price-adjustment clauses, and risk-sharing constructs gained traction as a mechanism to balance access and affordability while protecting clinical standards. Policymakers and industry leaders now emphasize resilience and adaptability as central design criteria for future commercial agreements and distribution frameworks.
Insightful segmentation analytics connecting indication diversity, provider ecosystems, distribution pathways, and dosing frequencies to optimize clinical and commercial tactics
Segmentation-driven strategies are essential to align clinical value propositions with the distinct characteristics of patient populations, care settings, distribution pathways, and dosing regimens. When considering indication-level differentiation, attention must be directed to each therapeutic area such as Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, because clinical presentation, progression risk, and treatment responsiveness vary and therefore warrant tailored evidence packages and stewardship protocols. End-user segmentation further refines commercial and operational priorities: ambulatory surgical centers operate under different throughput, billing, and inventory constraints compared with hospitals and ophthalmic clinics, which informs distribution agreements, cold-chain logistics, and onsite administration resources.
Distribution-channel dynamics are equally influential. Hospital pharmacy procurement environments favor bundled contracting and integrated inventory management, while online pharmacy channels introduce patient-centric convenience and different compliance considerations, and retail pharmacies require tailored dispensing workflows and patient education tools. Dosing frequency segmentation-ranging from As Needed regimens to Bimonthly and Monthly schedules-impacts adherence, clinic capacity planning, and long-term cost and outcome narratives. Aligning clinical trial designs, real-world evidence initiatives, and commercial messaging to these intersecting segmentation dimensions enables more precise targeting of reimbursement dossiers, provider engagement, and patient support programs, thereby improving uptake and preserving continuity of care across diverse settings.
A regionally nuanced perspective on regulatory, reimbursement, and delivery variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated access strategies
Regional dynamics materially influence regulatory pathways, reimbursement frameworks, service delivery models, and commercial approaches. In the Americas, payer heterogeneity and a strong private provider network create an environment where differentiated clinical evidence and contracting flexibility determine formulary positioning and access pathways. The Americas also tend to emphasize outcomes-based agreements in targeted segments and prioritize rapid adoption in high-volume treatment centers, while supply chain logistics are impacted by domestic manufacturing capacity and cross-border trade policies.
The Europe, Middle East & Africa region presents a complex mosaic of national health systems, regulatory regimes, and procurement practices. Centralized reimbursement evaluations coexist with decentralized hospital procurement, which requires manufacturers to pursue both health technology assessment engagement and local stakeholder partnerships. Price sensitivity and tender-driven purchasing models in several markets necessitate robust health economic dossiers and strategic local partnerships to secure durable access.
In the Asia-Pacific region, diverse levels of clinical infrastructure and variable reimbursement pathways create both rapid-adoption opportunities and access challenges. Some markets are characterized by fast uptake of innovation when supported by strong clinician advocacy and favorable reimbursement, whereas others require tiered pricing models and focused capacity-building initiatives. Across all regions, cold-chain integrity, point-of-care training, and locally relevant evidence are core enablers of sustained adoption and equitable patient access.
Actionable company-level intelligence describing how manufacturers, service providers, and distribution partners are reshaping R&D, contracting, and supply strategies to protect access
Leading companies and strategic partners in the retinal therapeutics domain are adapting commercial models and R&D priorities to the changing environment. Manufacturers with established products are investing in life-cycle management through new formulations, label expansions, and evidence generation that supports differentiated clinical value. Strategic alliances with contract manufacturing organizations and specialty distributors are being strengthened to secure supply continuity and to manage tariff-related cost pressures. Innovative entrants and established competitors alike are prioritizing head-to-head comparative trials and real-world outcome studies to substantiate claims of extended durability or superior functional improvement.
Service providers, including ambulatory surgical centers and specialty clinics, are optimizing procedural workflows and revenue models to accommodate evolving dosing schedules and to maximize throughput without compromising patient care. Contracting intermediaries and payers are experimenting with outcomes-based arrangements and bundled payment models to align incentives across the care continuum. Across this ecosystem, organizations that invest in integrated evidence strategies, digital patient support tools, and robust cold-chain logistics are better positioned to manage complexity and to preserve access in constrained procurement environments.
Practical strategic and operational recommendations for manufacturers, providers, and payers to safeguard access and optimize outcomes amid evolving clinical and commercial pressures
Industry leaders should adopt a multifaceted playbook that balances clinical differentiation, cost containment, and supply resiliency. First, evidence strategies must be prioritized to demonstrate not only clinical efficacy but also functional outcomes and total cost of care benefits; investing in pragmatic trials and high-quality registries will strengthen reimbursement discussions and provider confidence. Second, supply chain diversification and qualification of alternative suppliers, including validated nearshore partners, will mitigate tariff and logistics risks while preserving service levels.
Commercial teams should design flexible contracting constructs that incorporate risk-sharing elements and outcome-based milestones, aligning incentives among manufacturers, payers, and providers. Operationally, investing in predictive inventory analytics and enhanced cold-chain monitoring will reduce stockouts and wastage while enabling smoother patient pathways. Additionally, tailored engagement models for different provider types-ambulatory surgical centers, hospitals, and ophthalmic clinics-will improve adoption and adherence to recommended protocols. Finally, prioritizing patient support programs and telehealth-enabled follow-up can maintain adherence across varied dosing frequencies and reduce no-show rates, thereby preserving visual outcomes and smoothing resource utilization.
A transparent description of the mixed-methods research approach combining primary stakeholder interviews, document review, and scenario analysis to underpin strategic conclusions
This analysis integrates qualitative and quantitative research methods to deliver balanced, actionable insights. Primary research included structured interviews with key opinion leaders, procurement specialists, supply chain executives, and clinical operations managers to capture frontline perspectives on treatment patterns, access challenges, and operational constraints. Secondary research drew on peer-reviewed literature, regulatory public records, clinical trial registries, and payer policy documents to validate clinical and policy trends. Supply chain mapping and tariff impact analysis used transaction-level logic and scenario planning to explore potential pathways for cost and availability fluctuations.
Findings were triangulated through cross-validation with real-world use cases and advisory input from practicing retinal specialists. Limitations include the inherent unpredictability of policy changes and the emergence of new therapeutic entrants whose long-term impact may extend beyond the temporal window of this research. Nevertheless, the methodological mix of primary stakeholder engagement, rigorous document review, and scenario analysis provides a robust foundation for strategic decision-making and for prioritizing follow-up analyses tailored to specific organizational needs.
A concise synthesis of strategic implications and the imperative for coordinated clinical, commercial, and operational responses to protect patient outcomes
In sum, the Eylea landscape is at an inflection point where clinical innovation, commercial pressure, and geopolitical considerations intersect to redefine access and delivery. Clinicians and providers must adapt care pathways to accommodate evolving dosing paradigms and to ensure continuity of care in the face of procurement volatility. Manufacturers and distribution partners need to double down on evidence generation, supply chain diversification, and flexible contracting to preserve access while demonstrating value.
The implications are clear: tactical adjustments alone will not suffice; coordinated strategies that align clinical, commercial, and operational stakeholders are required to protect patient outcomes and to sustain service delivery. Prioritizing resilient logistics, targeted evidence accumulation, and collaborative contracting will enable stakeholders to navigate near-term disruptions and to capture long-term opportunities as the retinal therapeutics ecosystem continues to evolve.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of Eylea biosimilars challenging market exclusivity and pricing dynamics
- 5.2. Real-world data revealing variable treatment intervals and impact on patient outcomes
- 5.3. Adoption of treat-and-extend protocols to reduce injection burden in clinical practice
- 5.4. Pipeline innovations exploring sustained-release implants to extend Eylea dosing intervals
- 5.5. Competitive landscape shifts with emerging combination therapies targeting VEGF and PDGF pathways
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Eylea Market, by Indication
- 8.1. Age-Related Macular Degeneration
- 8.2. Branch Retinal Vein Occlusion
- 8.3. Central Retinal Vein Occlusion
- 8.4. Diabetic Macular Edema
- 8.5. Diabetic Retinopathy
- 9. Eylea Market, by Dosage Frequency
- 9.1. As Needed
- 9.2. Bimonthly
- 9.3. Monthly
- 10. Eylea Market, by End User
- 10.1. Ambulatory Surgical Centers
- 10.2. Hospitals
- 10.3. Ophthalmic Clinics
- 11. Eylea Market, by Distribution Channel
- 11.1. Hospital Pharmacy
- 11.2. Online Pharmacy
- 11.3. Retail Pharmacy
- 12. Eylea Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Eylea Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Eylea Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. AbbVie Inc
- 15.3.2. Adverum Biotechnologies Inc
- 15.3.3. Alcon Inc
- 15.3.4. Amgen Inc
- 15.3.5. Apellis Pharmaceuticals Inc
- 15.3.6. AstraZeneca plc
- 15.3.7. Bausch Health Companies Inc
- 15.3.8. Bayer AG
- 15.3.9. Biogen Inc
- 15.3.10. Eli Lilly and Company
- 15.3.11. Genentech Inc
- 15.3.12. GlaxoSmithKline plc
- 15.3.13. Johnson & Johnson
- 15.3.14. Kodiak Sciences Inc
- 15.3.15. Merck & Co., Inc.
- 15.3.16. Novartis AG
- 15.3.17. Ono Pharmaceutical Co., Ltd
- 15.3.18. Outlook Therapeutics Inc
- 15.3.19. Pfizer Inc
- 15.3.20. Regeneron Pharmaceuticals Inc
- 15.3.21. Roche Holding AG
- 15.3.22. Samsung Bioepis Co., Ltd
- 15.3.23. Sanofi S.A.
- 15.3.24. Santen Pharmaceutical Co., Ltd
- 15.3.25. Takeda Pharmaceutical Company Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
